COMMUNIQUÉS West-GlobeNewswire

RPX Enterprises and Xyngular Introduce XMD Wellness, a New Approach to Weight Loss and Wellness
05/11/2025
New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness accessible nationwide. XMD Wellness Logo MINERAL WELLS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE [...]
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
05/11/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SAFFRON, a [...]
Pennant Acquires Senior Living Communities in Idaho and Wisconsin
05/11/2025
EAGLE, Idaho, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces two [...]
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
05/11/2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug [...]
Pacific Health Care Organization, Inc. Reports its Third Quarter 2025 Financial Results
04/11/2025
Irvine, CA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q [...]
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
04/11/2025
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK ™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking [...]
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
04/11/2025
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the [...]
Precipio Announces Q3-2025 Shareholder Update Call
04/11/2025
Conference Call to be held on November 17th, 2025 at 5:00 PM EST NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2025 [...]
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
04/11/2025
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80 [...]
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
04/11/2025
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP [...]
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
04/11/2025
Châtillon, France, le 4 novembre (22 :30 CET) 2025 DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Anaptys Announces Participation in November Investor Conferences
04/11/2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
04/11/2025
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./ [...]
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
04/11/2025
SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, [...]
Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs
04/11/2025
November 4, 2025 Announcement no. 23 Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“ [...]
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
04/11/2025
November 4, 2025 Announcement no. 22 Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” [...]
Progress Update on BioPorto’s Adult Clinical Study
04/11/2025
November 4, 2025 Announcement no. 21 Progress Update on BioPorto’s Adult Clinical Study Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced [...]

Pages